IL33 and infection: The combination of both TMAO and CFT073 had significant additive effects on the release of IL-18R1 and synergistic effects on the release of IL-6, IL-24, IL-33, LIF, TGF-α, and LAP TGF-β1 compared to CFT073 infection alone (Figure 2).